Browse by author
Lookup NU author(s): Dr Guy MacGowanORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
To-date positive inotropic therapy in the treatment of congestive heart failure has resulted in adverse effects on long term survival. These agents increase calcium cycling through β-adrenergic stimulation or phosphodiesterase inhibition. An alternative method of producing positive inotropy is to increase the myofilament sensitivity to calcium. This can occur at several levels within the myofilament, and has potential benefits with respect to avoiding increased calcium cycling and producing a more favourable energy efficient positive inotropy. A potential adverse effect of increasing calcium sensitivity is slowed relaxation and diastolic dysfunction. We have learnt a considerable amount about the function of specific sites within the myofilament by the use of genetically engineered mouse models, which have shown diverse effects of various myofilament sites on global left ventricular function. Levosimendan is a novel inotropic agent that has several mechanisms of action including calcium sensitization, and is undergoing clinical trials at present. This review article will provide a comprehensive molecular, biophysical and physiological insight into the concepts underlying the myofilament force-calcium relationship and its potential as a target for positive inotropic therapy in heart failure. © 2005 Springer Science + Business Media, Inc.
Author(s): MacGowan GA
Publication type: Review
Publication status: Published
Journal: Cardiovascular Drugs and Therapy
Year: 2005
Volume: 19
Issue: 3
Pages: 203-210
Print publication date: 01/05/2005
ISSN (print): 0920-3206
ISSN (electronic): 1573-7241
URL: http://dx.doi.org/10.1007/s10557-005-2465-9
DOI: 10.1007/s10557-005-2465-9
PubMed id: 16142598
